Abstract: Objective To observe the clinical effect of sacubitril valsartan combined with Qili Qiangxin capsule in treating dilated cardiomyopathy with heart failure. Methods 83 patients with dilated cardiomyopathy and heart failure treated in the Department of Cardiovascular Medicine，Affiliated Hospital of Jianghan University from October 2019 to October 2020 were randomly divided into the observation group（42 cases） and the control group（41 cases）. The control group was treated with conventional therapy and sacubitril valsartan，and the observation group was given Qili Qiangxin capsule based on the treatment of the control group. After 12 weeks of treatment，the changes of serum NT-proBNP，left ventricular ejection fraction （LVEF） and left ventricular end-diastolic diameter （LVEDD） were compared between the two groups before and after treatment. Results After treatment，the serum NT-proBNP and LVEDD of the two groups were significantly decreased，and the LVEF was significantly increased， and the improvement of the above indexes in the observation group was better than that in the control group after treatment， and the difference was statistically significant（P < 0. 05）. After treatment，the total effective rate of the observation group was higher than that of the control group，and the difference was statistically significant（P < 0. 05）. Conclusion The effects of sacubitril valsartan combined with Qili Qiangxin capsule were better than sacubitril valsartan alone in treating dilated cardiomyopathy with heart failure.

Key words: dilated cardiomyopathy with heart failure, sacubitril valsartan, Qili Qiangxin capsule